LUND, Sweden, January 8, 2025 – Cellevate AB, an innovative biotech company commercializing next-generation cell culture systems designed to revolutionize biomanufacturing productivity of novel biotherapies by providing more than 300% higher productivity than current processes, today announced that Laura Chirica, CEO, will present a company overview at the JPM 2025 43rd Annual Healthcare Conference in San Francisco, CA, USA, on January 13. The presentation will highlight the commercial launch of the world’s first nanofiber-based cell culture system for gene therapy manufacturing as well as the current investment opportunity.
Event details – Cellevate presentation:
Date: Monday, January 13, 2025
Time: 11:00 AM
Track: Franciscan D (Ballroom Level)
Title: Cellevat3d® microcarriers – The world’s 1st nanofiber-based cell culture systems eliminate bottlenecks in biomanufacturing of gene therapies
For more information, please contact:
Laura Chirica, PhD
CEO Cellevate
Email: laura.chirica@cellevate.com
About Cellevate
Cellevate is a Swedish biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture systems for cell- and gene therapy and novel vaccines biomanufacturing. The core nanotechnology, Cellevat3d® is a sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of a new category of nanofiber cell culture systems – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to increased yield, productivity and process economy. Cellevat3d® nanofiber-based products are designed and validated as an integrated part of upstream bioprocessing solutions, from laboratory to large-scale production.
For more information, please visit www.cellevate.com.
